insights_auto
Why is 084990 up 2.21%?
Dive Deeperchevron_right
084990:KOSDAQ
Helixmith Co Ltd
₩3,700.00
arrow_upward
+2.21%(+80.00) 1D
Oct 30, 3:30:28 PM GMT+9 · KRW
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 084990...
Open
₩3,570
High
₩3,735
Low
₩3,550
Mkt. cap
170.54B
Avg. vol.
440.23K
Volume
134.60K
52-wk high
₩9,960
52-wk low
₩2,725
EPS
-₩35
Shares outstanding
46.09M
No. of employees
38
Open
₩3,570
High
₩3,735
Low
₩3,550
Mkt. cap
170.54B
Avg. vol.
440.23K
Volume
134.60K
52-wk high
₩9,960
52-wk low
₩2,725
EPS
-₩35
Shares outstanding
46.09M
No. of employees
38
News stories
From web sources and news partners
Yahoo Finance
·
23 minutes ago
Is the Vanguard S&P 500 ETF Still a Buy for Long-Term Investors? Here's My Honest Take.
The Globe and Mail
·
42 minutes ago
Should You Sell Your Stocks Right Now? Here's What a Century's Worth of History Suggests.
BigGo Finance
·
38 minutes ago
Wall Street's AI Trade Cracks: Nasdaq Sheds 2.86% as Alphabet, Intel Selloffs Expose Concentration Risk
CNBC
·
1 day ago
Anthropic's path to the Nasdaq just got a lot bumpier
Profile
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
About Helixmith Co Ltd